Walgreens Earnings: Tough Year Finishes With Disappointing Results and Challenges Likely in 2024
No-moat Walgreens Boots Alliance WBA reported weaker-than-expected fiscal fourth-quarter earnings, marking the end of a challenging year. Quarterly sales were up 9.2% year over year, but adjusted EPS of $0.67 fell 18% on constant currency. Walgreens continues to see headwinds in its overall business, including a normalization of respiratory events, lower COVID-19-related contributions (400,000 COVID-19 vaccinations administered in the fourth quarter versus 2.9 million in the prior-year quarter), labor pressures, shifting consumer behaviors, and a challenging macroeconomic environment. While year-over-year comparisons for 2024 appear likely to ease, these challenges may creep into next year, judging by the firm’s adjusted 2024 EPS guidance of $3.20-$3.50 compared with 2023′s $3.98. After updating our model for these near-term headwinds, we expect to lower our fair value estimate by a mid-single-digit percentage.
In the quarter, U.S. retail pharmacy was up 3.7% year over year thanks to strong comparable pharmacy sales, offset by weak retail sales, which were down 4.3%. Lower contributions from COVID-19-related items and weak prescription volume affected both channels. While we forecast some minor tailwinds from updated COVID vaccines in the first quarter of 2024, we expect full-year effects to be minimal.
The international segment had a solid quarter, with sales up 12.4%. An uptick in foot traffic, increase in basket size, and strong expansion in online sales drove growth across all categories, despite similar challenges to the U.S. market.
U.S. healthcare, a segment that we see as a key catalyst for future growth, reported roughly $2 billion in sales during the quarter with continued improvement in gross and operating margin. While scaling this business through clinic footprint expansion and key contract wins remains a positive sign, bottom-line growth has been slower than we expected, which continued quarter over quarter.
The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.